Neurobiological Technologies P/S 2024

Neurobiological Technologies Aktienanalyse

What does Neurobiological Technologies do?

Neurobiological Technologies Inc. (NTI) is an American company specializing in the research and development of new drugs for neurological disorders. It was founded in the 1980s by a team of neuroscientists focused on the treatment of stroke and traumatic brain injuries. NTI's business model is based on identifying promising targets within the nervous system and developing novel drugs that specifically target these targets. Through close collaboration with academic and clinical partners, NTI can rapidly develop new technologies and therapeutic approaches and bring them into the clinical phase. NTI is divided into various divisions focusing on different neurological disorders such as Parkinson's disease, Alzheimer's disease, and epilepsy. Each division is staffed with experts who have extensive experience in their respective research fields and collaborate closely with external partners. Over the years, NTI has developed several products at different stages of clinical development. One of the most promising products is XERECEPT, a synthetic peptide used for the treatment of brain tumors. The drug has shown promising results in clinical trials and has been submitted for market approval in the USA and Europe. Another promising product is Viprinex, a novel medication for the treatment of stroke patients. Viprinex is currently being tested in phase III of clinical development, and the results of the clinical trials are promising, suggesting that the drug may be approved in the near future. NTI is a pioneer in the field of neurology and has received several awards and accolades for its work. The company is also recognized in the academic community and has established partnerships with leading universities and research institutions. Overall, NTI is an innovative company specializing in the development of novel drugs for neurological disorders. It has achieved impressive successes in recent decades and is considered one of the most promising development companies in the field of neurology. Neurobiological Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Neurobiological Technologies's P/S Ratio

Neurobiological Technologies's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Neurobiological Technologies's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Neurobiological Technologies's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Neurobiological Technologies’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Neurobiological Technologies Stock

What is the price-to-earnings ratio of Neurobiological Technologies?

The price-earnings ratio of Neurobiological Technologies is currently 0.12.

How has the price-earnings ratio of Neurobiological Technologies changed compared to last year?

The price-to-earnings ratio of Neurobiological Technologies has increased by -84.42% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Neurobiological Technologies high compared to other companies?

Yes, the price-to-earnings ratio of Neurobiological Technologies is high compared to other companies.

How does an increase in the price-earnings ratio of Neurobiological Technologies affect the company?

An increase in the price-earnings ratio of Neurobiological Technologies would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Neurobiological Technologies affect the company?

A decrease in the price-earnings ratio of Neurobiological Technologies would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Neurobiological Technologies?

Some factors that influence the price-earnings ratio of Neurobiological Technologies are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Neurobiological Technologies pay?

Over the past 12 months, Neurobiological Technologies paid a dividend of 0.93 USD . This corresponds to a dividend yield of about 930,000 %. For the coming 12 months, Neurobiological Technologies is expected to pay a dividend of 0.93 USD.

What is the dividend yield of Neurobiological Technologies?

The current dividend yield of Neurobiological Technologies is 930,000 %.

When does Neurobiological Technologies pay dividends?

Neurobiological Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Neurobiological Technologies?

Neurobiological Technologies paid dividends every year for the past 0 years.

What is the dividend of Neurobiological Technologies?

For the upcoming 12 months, dividends amounting to 0.93 USD are expected. This corresponds to a dividend yield of 930,000 %.

In which sector is Neurobiological Technologies located?

Neurobiological Technologies is assigned to the '-' sector.

Wann musste ich die Aktien von Neurobiological Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Neurobiological Technologies from 12/27/2012 amounting to 0.05 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2012.

When did Neurobiological Technologies pay the last dividend?

The last dividend was paid out on 12/27/2012.

What was the dividend of Neurobiological Technologies in the year 2023?

In the year 2023, Neurobiological Technologies distributed 0 USD as dividends.

In which currency does Neurobiological Technologies pay out the dividend?

The dividends of Neurobiological Technologies are distributed in USD.